Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine 7/7 Schedule in Metastatic Breast Cancer
NCT02028494Unknown
- Sponsor
- Latin American and Caribbean Society of Medical Oncology
- Start
- Aug 2013
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Latin American and Caribbean Society of Medical Oncology. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02028494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028494.